JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
TEMPLE CITY, Calif., Oct. 25, 2016 -- Fulgent Genetics, Inc. (Nasdaq:FLGT) (“Fulgent Genetics” or the “company”) today announced that Ming Hsieh, its Chairman and Chief Executive Officer, Dr. Harry Gao, its Chief Science Officer, and Paul Kim, its Chief Financial Officer, are scheduled to present at the 25th Annual Credit Suisse Healthcare Conference at the Phoenician hotel in Scottsdale, Arizona on Monday, November 7, 2016 at 4:00 PM MST (3:00 PM PST).
The live audio webcast and accompanying slide presentation can be accessed in the Investor Relations section of the company’s website, www.fulgentgenetics.com, and an audio replay of the webcast will remain available on the company’s website through December 7, 2016.
About Fulgent Genetics, Inc.
Fulgent Genetics is a rapidly growing technology company with an initial focus on offering comprehensive genetic testing to provide physicians with clinically actionable diagnostic information they can use to improve the overall quality of patient care. The company has developed a proprietary technology platform that integrates sophisticated data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes. This platform allows the company to offer a broad and flexible test menu while maintaining accessible pricing, high accuracy, and competitive turnaround times. The company believes its current test menu, which includes more than 18,000 single-gene tests and more than 200 pre-established, multi-gene, disease-specific panels, offers more genes for testing than its competitors in today’s market, which enables it to provide expansive options for test customization and clinically actionable results.
Investor Contacts The Blueshirt Group Bob Jones, 212-871-5570, [email protected] Chris Danne, 415-217-5865, [email protected]
